Hims & Hers Health (NYSE:HIMS) CFO Sells $261,377.87 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 7,163 shares of the stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $36.49, for a total transaction of $261,377.87. Following the sale, the chief financial officer directly owned 284,321 shares in the company, valued at approximately $10,374,873.29. The trade was a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total value of $619,243.91.
• On Monday, May 18th, Oluyemi Okupe sold 7,950 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.64, for a total value of $187,938.00.
• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.96, for a total value of $588,564.20.
• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.90, for a total value of $956,279.80.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.83, for a total value of $501,079.15.

Hims & Hers Health Stock Down 1.5%

Hims & Hers Health stock opened at $35.53 on Friday. The stock has a market capitalization of $8.22 billion, a PE ratio of -394.80, a price-to-earnings-growth ratio of 101.51 and a beta of 2.35. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The business has a 50 day simple moving average of $29.21 and a 200-day simple moving average of $26.34. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. During the same period in the prior year, the business posted $0.20 EPS. Hims & Hers Health’s revenue was up 3.8% compared to the same quarter last year. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on HIMS shares. Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. lowered their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Needham & Company LLC upped their price objective on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, Bank of America increased their price objective on shares of Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a report on Thursday. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $30.70.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC raised its position in Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. SG Americas Securities LLC boosted its position in shares of Hims & Hers Health by 25.6% during the fourth quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock worth $12,064,000 after buying an additional 75,679 shares during the period. Vanguard Group Inc. boosted its position in shares of Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares during the period. Munich Reinsurance Co Stock Corp in Munich acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at $11,187,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Hims & Hers Health in the third quarter valued at $5,233,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.